Novo Nordisk, as well as Eli Lilly, would get Medicare and Medicaid coverage for their successful slimming drugs.
The Trump administration is negotiating a deal with the weight-loss drug companies Eli Lilly and Novo Nordisk. This would allow them to sell lower doses of some of their obesity drugs to consumers at $149 for a monthly supply through TrumpRx (*), according to people familiar with the matter.
The drugs have list prices ranging from about $1,000 to $1,350 per month. The companies offer discounts to both insurers and patients, including cash prices of about $499 per month for patients using the companies’ direct purchasing services. Source : The Wall Street Journal
(*) a government-run website, dubbed TrumpRx, to allow consumers to buy drugs directly from manufacturers. GLP1 is discussed here but also in this article.
